Why drug cost hasn't been the biggest hurdle in eliminating hep C; Akero treatment for NASH reduces liver scarring

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by       With a promising new plan to pay for pricey cures, two states set out to eliminate hepatitis C. But cost hasn't been the biggest problem By Nicholas Florko Experts assumed the biggest obstacle to eliminating hep C was the sky-high cost of a cure. An investigation reveals more intractable issues. Read More STAT+: Akero treatment for NASH reduces liver scarring, achieves goals of mid-stage study By Adam Feuerstein Adobe Akero reported encouraging results for its drug aimed at ameliorating the effects of NASH, which can lead to liver cancer and transplantation. Read More Opinion: Vaccine guarantees can help prevent the resurgence of polio By Awi Federgruen Ezra Acayan/Getty Images One way to avoid the looming shortfall of polio vaccines: Create an advance market commitment that will guarantee manufacturers of purchases. Read More Sponsor content by AMERISOURCEBERGEN Checklist: 5 steps to improved medication adherence Addressing medication adherence is just one part of a biopharma company's commercialization strategy. Overcoming the myriad factors that can contribute to non-adherence is a daunting task. For companies who have moved the needle, success means a multi-step, multi-faceted approach. Download this checklist to use as you address clinical and non-clinical hurdles, and help get more patients the treatments they need. Opinion: Health care needs a Black Friday sale: the case for legalizing discounts on medical services By Stacy Bratcher Adobe Eliminating the legal ban on patient discounts would empower health care providers and consumers to drive down costs. Read More Tuesday, September 13, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser